Related Experiment Videos
Effect of calcium channel blocker (diltiazem) on platelet aggregation
S R Salam1, R Saxena, A K Saraya
1Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi.
Insights
Diltiazem effectively inhibits platelet aggregation at higher concentrations, suggesting its potential as an antiplatelet drug. Further research could explore its synergistic use with other antiplatelet medications.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Platelet aggregation plays a crucial role in thrombosis.
- Understanding agents that modulate platelet function is vital for cardiovascular health.
- Diltiazem is a calcium channel blocker with potential pleiotropic effects.
Purpose of the Study:
- To investigate the antiplatelet properties of diltiazem.
- To determine the effective concentrations of diltiazem for inhibiting platelet aggregation.
- To explore the clinical utility of diltiazem as an antiplatelet agent.
Main Methods:
- In vitro assessment of platelet aggregation.
- Testing diltiazem at varying concentrations (0.48, 0.24, and 0.024 mg/ml).
- Stimulation of platelet aggregation using collagen, adenosine diphosphate (ADP), and sodium arachidonate.
Main Results:
- Significant inhibition of platelet aggregation observed with diltiazem at 0.48 mg/ml and 0.24 mg/ml.
- No significant antiplatelet effect was noted at the lowest concentration (0.024 mg/ml).
- Diltiazem demonstrates dose-dependent inhibition of platelet aggregation.
Conclusions:
- Diltiazem exhibits significant antiplatelet activity at pharmacologically relevant concentrations.
- The antiplatelet effects of diltiazem warrant clinical investigation.
- Diltiazem may be a valuable adjunct therapy, potentially used synergistically with other antiplatelet drugs.
Abstract:
Platelet aggregation with collagen, ADP and sodium arachidonate was significantly inhibited by 0.48 and 0.24 mg/ml of diltiazem but no significant effect occurred with 0.024 mg/ml of diltiazem. It is suggested that the antiplatelet property of diltiazem may be utilized in clinical setting and diltiazem may be tried synergistically with other antiplatelet drugs.